Tarkistin, miten BA.4 menestyy maailmanmatkallaan ja näyttääpä se menestyvän. Nyt siitä on mainittuna 1333 sekvenssiä Ne jakantuvat eri maihin seuraavasti:
EteläAfrikassa 820 (2%) , (Muut ovat prosentulaaisti 0%), USA:ssa 119, UK:ssa 91, Itävallassa 80, Tanskassa 43, Belgiassa 34, Saksassa 33, Italiassa 24,Israelissa 24, Australiassa 19, Hollannissa 11, Espanjassa 10,Ranskassa 7, Kanadassa 7 Singaporessa 3, Sveitsissä 3, Irlannissa 2 sekvenssiä , Chilessä 1, Uudessa Seelannissa 1. Botswanassa 1 sekvenssi.
BA.4 Publications & Resources
5 results
Publication
Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies Daichi Yamasoba et al.bioRxiv 3 May 2022
Publication
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection Yunlong Richard Cao et al.bioRxiv 2 May 2022
Publication
Continued Emergence and Evolution of Omicron in South Africa: New BA.4 and BA.5 lineages Houriiyah Tegally et al.medRxiv 2 May 2022.Sa uth Africas fourth COVID-19 wave was driven predominantly by three
lineages (BA.1, BA.2 and BA.3) of the SARS-CoV-2 Omicron variant of
concern. We have now identified two new lineages, BA.4 and BA.5. The
spike proteins of BA.4 and BA.5 are identical, and comparable to BA.2
except for the addition of 69-70del, L452R, F486V and the wild type
amino acid at Q493. The 69-70 deletion in spike allows these lineages to
be identified by the proxy marker of S-gene target failure with the
TaqPath COVID-19 qPCR assay. BA.4 and BA.5 have rapidly replaced BA.2,
reaching more than 50% of sequenced cases in South Africa from the first
week of April 2022 onwards. Using a multinomial logistic regression
model, we estimate growth advantages for BA.4 and BA.5 of 0.08 (95% CI:
0.07 - 0.09) and 0.12 (95% CI: 0.09 - 0.15) per day respectively over
BA.2 in South Africa.
Publication
Omicron sub-lineages BA.4/BA.5 escape BA.1 infection elicited neutralizing immunity Khadija Khan et al.medRxiv 1 May 2022
Publication
The
SARS-CoV-2 variant, Omicron, shows rapid replication in human primary
nasal epithelial cultures and efficiently uses the endosomal route of
entry. Thomas P. Peacock et al.bioRxiv 3 January 2022
Inga kommentarer:
Skicka en kommentar